Search research articles
Contact Us
Filters
Showing results (21-30 of 52) with videos related to
Page
of 6
Sort By:
Psychopharmacology Bulletin
|
August 1, 2008
Criteria for defining symptomatic and sustained remission in bipolar I disorder: a post-hoc analysis of a 26-week aripiprazole study (study CN138-010)
Prakash S Masand, James Eudicone, Andrei Pikalov, et al.
The American Journal of Psychiatry
|
April 3, 2008
Efficacy of adjunctive aripiprazole to either valproate or lithium in bipolar mania patients partially nonresponsive to valproate/lithium monotherapy: a placebo-controlled study
Eduard Vieta, Caroline T'joen, Robert D McQuade, et al.
The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry
|
November 3, 2007
Aripiprazole for the treatment of psychoses in institutionalized patients with Alzheimer dementia: a multicenter, randomized, double-blind, placebo-controlled assessment of three fixed doses
Jacobo E Mintzer, Larry E Tune, Christopher D Breder, et al.
Psychopharmacology
|
September 6, 2006
Intramuscular aripiprazole for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder: a double-blind, placebo-controlled comparison with intramuscular haloperidol
Raisa Andrezina, Richard C Josiassen, Ronald N Marcus, et al.
The Journal of Clinical Psychiatry
|
August 5, 2011
Safety and tolerability of aripiprazole for irritability in pediatric patients with autistic disorder: a 52-week, open-label, multicenter study
Ronald N Marcus, Randall Owen, George Manos, et al.
The Journal of Clinical Psychiatry
|
June 27, 2007
The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study
Robert M Berman, Ronald N Marcus, René Swanink, et al.
Pediatrics
|
December 2, 2009
Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder
Randall Owen, Linmarie Sikich, Ronald N Marcus, et al.
The Journal of Clinical Psychiatry
|
May 17, 2007
Aripiprazole effects in patients with acute schizophrenia experiencing higher or lower agitation: a post hoc analysis of 4 randomized, placebo-controlled clinical trials
Stephen R Marder, Britt West, Gina S Lau, et al.
Journal of Clinical Psychopharmacology
|
January 22, 2008
Aripiprazole monotherapy in nonpsychotic bipolar I depression: results of 2 randomized, placebo-controlled studies
Michael E Thase, Alan Jonas, Arif Khan, et al.
Movement Disorders : Official Journal of the Movement Disorder Society
|
October 3, 2006
Open-label flexible-dose pilot study to evaluate the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson's disease
Joseph H Friedman, Robert M Berman, Christopher G Goetz, et al.
Page
of 6
Search research articles
Search
Showing results (21-30 of 52) with videos related to
Sort By:
Page
of 6
Psychopharmacology Bulletin
|
August 1, 2008
Criteria for defining symptomatic and sustained remission in bipolar I disorder: a post-hoc analysis of a 26-week aripiprazole study (study CN138-010)
Prakash S Masand, James Eudicone, Andrei Pikalov, et al.
The American Journal of Psychiatry
|
April 3, 2008
Efficacy of adjunctive aripiprazole to either valproate or lithium in bipolar mania patients partially nonresponsive to valproate/lithium monotherapy: a placebo-controlled study
Eduard Vieta, Caroline T'joen, Robert D McQuade, et al.
The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry
|
November 3, 2007
Aripiprazole for the treatment of psychoses in institutionalized patients with Alzheimer dementia: a multicenter, randomized, double-blind, placebo-controlled assessment of three fixed doses
Jacobo E Mintzer, Larry E Tune, Christopher D Breder, et al.
Psychopharmacology
|
September 6, 2006
Intramuscular aripiprazole for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder: a double-blind, placebo-controlled comparison with intramuscular haloperidol
Raisa Andrezina, Richard C Josiassen, Ronald N Marcus, et al.
The Journal of Clinical Psychiatry
|
August 5, 2011
Safety and tolerability of aripiprazole for irritability in pediatric patients with autistic disorder: a 52-week, open-label, multicenter study
Ronald N Marcus, Randall Owen, George Manos, et al.
The Journal of Clinical Psychiatry
|
June 27, 2007
The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study
Robert M Berman, Ronald N Marcus, René Swanink, et al.
Pediatrics
|
December 2, 2009
Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder
Randall Owen, Linmarie Sikich, Ronald N Marcus, et al.
The Journal of Clinical Psychiatry
|
May 17, 2007
Aripiprazole effects in patients with acute schizophrenia experiencing higher or lower agitation: a post hoc analysis of 4 randomized, placebo-controlled clinical trials
Stephen R Marder, Britt West, Gina S Lau, et al.
Journal of Clinical Psychopharmacology
|
January 22, 2008
Aripiprazole monotherapy in nonpsychotic bipolar I depression: results of 2 randomized, placebo-controlled studies
Michael E Thase, Alan Jonas, Arif Khan, et al.
Movement Disorders : Official Journal of the Movement Disorder Society
|
October 3, 2006
Open-label flexible-dose pilot study to evaluate the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson's disease
Joseph H Friedman, Robert M Berman, Christopher G Goetz, et al.
Page
of 6